卵巢癌相关文献与解析，生知库 | 链接生命科学的每一步

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验：在初诊晚期卵巢癌患者中，使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价（FZOCUS-1）：一项多中心、随机、双盲、安慰剂对照试验

Wu, Lingying; Wang, Jing; Li, Qingshui; Wang, Danbo; Zhang, Cuiying; Tang, Junying; Zhang, Guonan; Hao, Min; Yao, Desheng; Gao, Qinglei; Zhang, Youzhong; An, Ruifang; Yin, Rutie; Wang, Li; Xia, Bairong; Zhou, Qi; Yang, Hongying; Zhu, Jianqing; Jiang, Kui; Chen, Zhengzheng; Wu, Qiang; Duan, Wei; Huang, Yi; Zhang, Hui; Wei, Shuqing; Li, Guiling; Meng, Yuanguang; Wang, Ke; Yang, Xinfeng; Huang, Xianghua; Pan, Lingya; Yu, Jinjin; Lou, Ge; Zhang, Yu; Zhou, Huaijun; Guo, Xiaoqing; Yang, Hong; Cheng, Xiaodong; Li, Xiumin; Wang, Wuliang; Zhao, Hongqin; Li, Yunxia; Yang, Yingjie; Lin, An; Cheng, Wenjun; Chen, Lihong; Xie, Xiaoying; Di, Wen; Hu, Yuanjing; Chen, Mo; Wen, Hongwu; Cai, Liping; Wu, Xiaohua; Lin, Zhongqiu; Wang, Quanren; Yang, Xinfeng; Li, Ning

肿瘤

Diagnostic tests for ovarian cancer in premenopausal women with non-specific symptoms (ROCkeTS): prospective, multicentre, cohort study

针对绝经前非特异性症状女性卵巢癌的诊断性检查（ROCkeTS）：一项前瞻性、多中心队列研究

期刊:Bmj-British Medical Journal

影响因子:42.7

doi:10.1136/bmj-2024-083912

Sundar, Sudha; Agarwal, Ridhi; Scandrett, Katie; Davenport, Clare; Van Calster, Ben; Johnson, Susanne; Sengupta, Partha; Selvi-Vikram, Radhika; Kwong, Fong Lien; Mallett, Sue; Rick, Caroline; Kehoe, Sean; Timmerman, Dirk; Bourne, Tom; Stobart, Hilary; Neal, Richard D; Menon, Usha; Gentry-Maharaj, Aleksandra; Sturdy, Lauren; Ottridge, Ryan; Deeks, Jonathan J

Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer

泛素介导的KDM5B稳定化通过抑制双特异性磷酸酶4驱动卵巢癌的化疗耐药性

期刊:Signal Transduction and Targeted Therapy

影响因子:40.8

doi:10.1038/s41392-026-02601-y

Jung Yoo,Go Woon Kim,Yu Hyun Jeon,Jaewook Kim,Enzhi Luo,Sang Wu Lee,Soo Yeon Oh,Junjeong Choi,Kuglae Kim,So Hee Kwon

IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer

IL-12释放纳米颗粒用于转移性卵巢癌的有效免疫治疗

期刊:Nature Materials

影响因子:38.5

doi:10.1038/s41563-025-02390-9

Pires, Ivan S; Covarrubias, Gil; Gomerdinger, Victoria F; Backlund, Coralie; Nombera Bueno, Eduardo; Billingsley, Margaret M; Pryor, Mae; Shanker, Apoorv; Gordon, Ezra; Wu, Shengwei; Pickering, Andrew J; Melo, Mariane B; Suh, Heikyung; Irvine, Darrell J; Hammond, Paula T

Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer

撤稿声明：肿瘤进展过程中AMPK-β1表达降低会增强晚期卵巢癌的致癌能力

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-026-02635-4

Li, Cuilan; Liu, Vincent Ws; Chiu, Pui Man; Yao, Kwok-Ming; Ngan, Hextan Ys; Chan, David W

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

用于检测结直肠癌、肺癌和卵巢癌的复合蛋白质组学和代谢组学血浆生物标志物

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-026-02654-1

Ögren, Jim Åkerrén; Ekström, Joakim; Rameika, Natallia; Torell, Emma; Larsson, Chatarina; Stoimenov, Ivaylo; Micke, Patrick; Gyllensten, Ulf; Hellström, Mats; Glimelius, Bengt; Stålberg, Karin; Sjöblom, Tobias

Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair

利用合成致死性治疗上皮性卵巢癌：超越DNA损伤修复的多维度策略

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-025-02562-w

Bigdeli, Mandana; Tremblay, Elizabeth; Provencher, Diane; Mes-Masson, Anne-Marie; Rodier, Francis

Micropeptide YG-6 encoded by exosomal LINC01123 derived from highly migratory ovarian cancer cells promotes tumor progression.

由高度迁移的卵巢癌细胞衍生的外泌体 LINC01123 编码的微肽 YG-6 可促进肿瘤进展。

期刊:Molecular Cancer

影响因子:33.9

doi:10.1186/s12943-026-02621-w

Lei Han, Zhou Zhengwei, Li Chengyuan, Fan Lili, Wu Qihan, Wang Maonan, Guo Ke, Pan Qiong, Mor Gil, Shu Guang, Li Juanni, Yin Gang

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

Suvemcitug联合化疗治疗铂类耐药复发性卵巢癌：SCORES随机、双盲、3期试验

期刊:Nature Cancer

影响因子:28.5

doi:10.1038/s43018-025-01085-z

Yuan, Guangwen; Lou, Ge; Li, Jundong; Xu, Mei; Liu, Xiaowei; Wang, Danbo; Zhang, Keqiang; Zhu, Tao; Li, Xiumin; Huang, Yi; Duan, Wei; Wang, Ke; Zhou, Qi; Li, Guiling; Yang, Chen; Zhang, Jiajing; Sun, Haolin; Tang, Renhong; Li, Qingshui; Wu, Lingying

Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness

卵巢癌一线治疗后的维持治疗：定量疗效

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

一项多中心、随机、双盲、安慰剂对照的3期临床试验：在初诊晚期卵巢癌患者中，使用氟哌啶醇联合或不联合阿帕替尼作为维持治疗方案的疗效评价（FZOCUS-1）：一项多中心、随机、双盲、安慰剂对照试验

Diagnostic tests for ovarian cancer in premenopausal women with non-specific symptoms (ROCkeTS): prospective, multicentre, cohort study

针对绝经前非特异性症状女性卵巢癌的诊断性检查（ROCkeTS）：一项前瞻性、多中心队列研究

Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer

泛素介导的KDM5B稳定化通过抑制双特异性磷酸酶4驱动卵巢癌的化疗耐药性

IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer

IL-12释放纳米颗粒用于转移性卵巢癌的有效免疫治疗

Retraction Note: Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer

撤稿声明：肿瘤进展过程中AMPK-β1表达降低会增强晚期卵巢癌的致癌能力

Composite proteomic and metabolomic plasma biomarkers for detection of colorectal, lung and ovarian cancers

用于检测结直肠癌、肺癌和卵巢癌的复合蛋白质组学和代谢组学血浆生物标志物

Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair

利用合成致死性治疗上皮性卵巢癌：超越DNA损伤修复的多维度策略

Micropeptide YG-6 encoded by exosomal LINC01123 derived from highly migratory ovarian cancer cells promotes tumor progression.

由高度迁移的卵巢癌细胞衍生的外泌体 LINC01123 编码的微肽 YG-6 可促进肿瘤进展。

Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial

Suvemcitug联合化疗治疗铂类耐药复发性卵巢癌：SCORES随机、双盲、3期试验